Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital.

Division of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway.
Acta oncologica (Stockholm, Sweden) (Impact Factor: 2.27). 05/2008; 47(8):1475-82. DOI: 10.1080/02841860802047387
Source: PubMed

ABSTRACT The aim of this study was to determine the prevalence and outcome of radiation-induced sarcomas (RISs) among sarcoma patients referred to the Norwegian Radium Hospital (NRH).
Ninety patients were identified from the institutional sarcoma data base. Medical records and histological and cytological material from both primary and secondary tumours were reviewed.
RIS represented 3.0 % of the sarcomas in the data base. The median latency time from radiotherapy of the primary tumour to the diagnosis of RIS was 13.6 years (range 2.5-57.8 years). Gynaecological, breast and testicular cancers were the most common primary diagnoses. For the RISs 13 different histological types were identified including 25 malignant fibrous histiocytomas (28% of all) and 22 osteosarcomas (24%). The sarcoma-related 5-year crude survival was 33% (95 % CI 23-43 %). Unfavourable prognostic factors were metastases at presentation, incomplete surgery and presence of tumour necrosis.
Radiation-induced sarcoma is rare and harbours an aggressive clinical behaviour. Complete surgical resection is mandatory for cure.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To study the clinical and histological features of radiation-induced sarcoma in the head and neck (RISHN). Medical records of 13 patients with RISHN treated at our institution between 1990 and 2011 were studied, and paraffin-embedded samples were analyzed by haematoxylin and eosin staining and immunohistochemistry to determine mitosis counts and assess expression of Ki-67, bcl-2, and survivin. Positive bcl-2 was observed in 12 (100%) and survivin in 10 (76.9%) patients. The Ki-67 labeling index ranged from 1% to 90%, and it showed significant positive correlation with mitosis count in RISHN tissues, based on Spearman analysis. Percentage of distal metastasis with T2b was significantly higher than T1b stage (P=0.035). Stage T2b may be a useful indicator for predicting distant metastasis of RISHN. The MIB-1 score may be used as a histological grading system for RISHN. In addition, bcl-2 and survivin protein may play an important role in pathogenesis and progression of RISHN.
    Asian Pacific journal of cancer prevention: APJCP 01/2011; 12(11):2995-9. · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is an increasing recognition of the importance of genetic and familial cancer syndromes in routine clinical practice. Although most of gastrointestinal cancers are sporadic, a number of important cancer predisposition syndromes are now recognized and well characterized. In this review, we discuss some of the basic principles of clinical cancer genetics and clinically relevant aspects of the more common gastrointestinal cancer syndromes from the perspective of practicing radiation oncologists.
    American journal of clinical oncology 06/2011; 34(3):332-6. · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Studies on second sarcoma in unselected populations of cancer survivors have not previously been published. Second sarcoma was defined as a sarcoma following a previous invasive cancer. Patients with this malignancy were retrieved from the Cancer Registry in Norway for the period 1960-2007 among a total of 728874 cancer patients including 11 612 with a sarcoma. Changes in incidence and average annual percent change (AAPC) were studied with join-point analyses. Overall and sarcoma-related mortalities were assessed using the Kaplan-Meier and competing risk methods, respectively. A total of 900 second sarcomas were identified comprising 7.5% of all sarcomas. The AAPC of second sarcoma incidence was 6.2 (95% CI=5.7-6.7) as compared to 2.5 (95% CI=2.1-2.8) for all sarcomas and 2.5 (95% CI=2.4-2.6) for cancer in general. The annual incidence of second sarcomas doubled during the last decade of the study period. The distribution of histological subtypes was significantly different between second and sporadic sarcomas. The overall mortality was significantly higher and sarcoma-related mortality was significantly lower for patients with a second sarcoma compared to sporadic sarcoma. There is an increasing incidence of second sarcomas among cancer survivors, and one may speculate a relation to the intensified use of cytotoxic treatment of the preceding malignancy. Sarcoma-related mortality after second sarcomas is significantly below that of sporadic sarcoma.
    European journal of cancer (Oxford, England: 1990) 06/2013; · 4.12 Impact Factor